Stems Cells and The Price of Immortality  by Holland, Andrew M. & Stanley, Edouard G.
ava i l ab l e a t www.sc i enced i r ec t . com
www.e l sev i e r. com/ l oca te / sc r
Stem Cell Research (2009) 2, 26–28ON THE TOPIC
Stems Cells and The Price of Immortality
Andrew M. Holland ⁎, Edouard G. StanleyMonash Immunology and Stem Cell Laboratories (MISCL), Level 3, Building 75, Monash University, Clayton,
Victoria 3800, AustraliaReceived 2 November 2008; accepted 2 November 2008Contents
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28Creating β cells for the treatment of diabetes has been
one of the most avidly pursued goals in the field of stem cell
differentiation. A steady stream of publications over the last
few years has demonstrated that β-like cells can be
generated from embryonic stem cells (ESCs) (reviewed in
Baetge, 2008) and that in some instances, these cells can
modulate blood glucose levels in diabetic mice (Jiang et al.,
2007; Kroon et al., 2008). These kinds of studies have
galvanised efforts to improve the efficiency and efficacy of
human ESC differentiation protocols aimed at generating this
particular cell type.
The attraction of human ESCs as a platform for generating
β cells lies in their immortality and the potential to direct
their differentiation under defined, scalable conditions.
However, in most instances, differentiation of human ES
cells toward specific cell-fates, including insulin-expressing
cells, is relatively inefficient. In part, this is because the
course of differentiation is influenced by poorly defined
components such as the composition of the culture media,
feeder cells and extra cellular matrices. Although many of⁎ Corresponding author. Monash Immunology and Stem Cell
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doi:10.1016/j.scr.2008.11.002these parameters may eventually be controlled (Ng et al.,
2008), variability inherent in the ESCs themselves may make
the generation of semi-purified populations of β cells a
continuing challenge. Indeed, even protocols that can
generate relatively pure populations of endodermal progeni-
tors still must contend with the propensity of these
progenitors to generate a diverse variety of end cells
(D'Amour et al., 2005; D'Amour et al., 2006). In this respect,
the ability of ESCs to generate a variety of cell types
represents a two edged sword, providing an opportunity to
produce any desired cell type on the one hand balanced
against the need maintain control over the course of
differentiation on the other.
One approach to circumventing the heterogeneous
mixture of cell types generated with ESC based differentia-
tion protocols would be to derive immortal progenitor cells
whose differentiation potential was restricted to the
lineages of interest. Although immortalisation of normal
cell types has rarely been achieved, lessons from ESC biology
provide hope that this might be possible.
Inner cell mass (ICM) cells of the blastocyst, from which
ESCs are derived, represent a transient population of cells
that follow an inexorable developmental pathway of
differentiation, ultimately resulting in the generation of a
new animal or individual. Thus, ‘immortalisation’ of ICM cells
in vitro to generate ESCs represents a profound deviation
27Stems and immortalityfrom the developmental pathway normally followed by these
cells in vivo. This immortalisation is a consequence of the
displacement of the ICM cells from their native environment
and their culture in exogenous factors which permit
proliferation and suppress differentiation (Brons et al.,
2007). That immortality can be achieved through the
application of appropriate culture conditions raises the
possibility of deriving of lineage-restricted ‘stem’ cell lines
that may be used to derive germ-layer or tissue-specific cell
types with less risk of uncontrolled multi-lineage differentia-Figure 1 Ontological relationship between immortalized cells
Immortalisation of lineage restricted progenitor cells may provide a m
types can be generated in vitro. However, it still remains to be det
genetic stability or integrity. Question marks indicate that the mech
progenitor cell stages has yet to be clearly elucidated.tion (Fig. 1). In theory, the only roadblock to this approach
may be identification of the appropriate combination of
factors that confer in vitro immortality.
In this issue, two reports from the laboratory of Sai-Kang
Lim describe the generation of immortalised insulin-produ-
cing cell lines from a population of lineage-restricted stem
cells (Li et al., 2009a; Li et al., 2009b). Lim has previously
reported the derivation of lineage-restricted cell lines
derived from embryonic day 5-6 embryos (RoSH cells) or
mESC's (E-RoSH cells) and demonstrated their propensity tolines with progressively restricted developmental potential.
eans of improving the efficiency with which specific mature cell
ermined if immortality can be achieved without compromising
anism for self renewal at the germ layer- and tissue-restricted
28 A.M. Holland, E.G. Stanleydifferentiate into endothelial cells (Lian et al., 2006; Yin et
al., 2004). In the present studies, this group has further
characterised these cell-lines and demonstrated that both
possess gene expression profiles more similar to mesendo-
derm, rather than mESCs. Through a combined process of
maturation and attrition, the authors were able to derive
clonal insulin-producing cell lines that displayed the proper-
ties of functionally immature, fetal-like β-cells. Despite
their immature phenotype, these cell lines were able to
reduce blood glucose in animals with chemically induced
diabetes.
However, closer analysis of these cells revealed that they
possessed some properties of transformed cell lines; namely
persistent growth following transplantation and an inability
to take the last step in differentiation toward regulated
insulin release. Moreover, the authors noted that cells
displayed a tendency for chromosomal instability, another
property common to tumor-derived lines. It therefore
appears that in this case, immortality may have come at a
high price.
The cost of immortality highlighted in these studies has
wider implications for the field of stem cells and, in
particular, induced pluripotent stem cells (iPS). Like the
work described by Sai Kang Lim in this issue, iPS protocols
rely on a combination of selection and attrition to isolate
reprogrammed cells that display ESC like properties (Taka-
hashi et al., 2007). In most cases, reprogramming takes a
number of weeks and involves the emergence of a rare ESC-
like phoenix from the ashes of the vast numbers of somatic
cells that have succumbed to their own mortality. In the case
of the newly derived iPS cells, it is still unclear whether
immortality occurs as a consequence of the target cell being
converted to an ESC like state or whether infrequent targets
exist that have a genetic predisposition for immortality that
is played upon by reprogramming factors. This question will
not be resolved until the frequency of reprogramming can be
significantly improved.
The above discussion about the requirement for repro-
gramming in the case of iPS cells will also be relevant to
attempts to derive immortal lineage restricted stem cells.
On the positive side, studies such as those of Sai Kang Lim
may be a necessary preamble in the same way that work with
embryonal carcinoma cells provided the groundwork for the
eventual isolation of ESCs (Bradley et al., 1998).Acknowledgments
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